Menopause Testosterone: Impact on Libido & Treatment

Menopause Testosterone and Libido: Evidence-Based Insights

Hypoactive sexual desire disorder is a common and distressing symptom for many women in the menopause transition, affecting up to 40% of postmenopausal individuals. Research increasingly points to the decline of testosterone, not just estrogen, as a key physiological driver. A 2026 literature review from Florida International University highlights a central clinical paradox: despite nearly a century of use and consistent patient demand, no testosterone product is approved for women in the United States.

Symptom-Based Diagnosis Trumps Unreliable Blood Tests

Diagnosing testosterone deficiency in women is notoriously difficult. The Florida International University review notes that due to inconsistent laboratory assays and natural hormonal variability, serum levels are an unreliable guide. A level considered “normal” for one woman may be insufficient for another. Instead, a symptom-based clinical approach is recommended. The core symptom is a noticeable and bothersome loss of sexual desire, often accompanied by reduced sensitivity and an inability to become aroused. Fatigue and depressed mood are also common concurrent complaints. This focus on patient-reported experience aligns with newer guidance, such as the ALEG Position Statement on Evidence, which prioritizes treating the patient, not the lab value.

Transdermal Gels Deliver Consistent Hormone Levels

A practical study from 2026 adds clarity on how to safely administer testosterone. Researchers at the University of Manchester, led by Adrian Heald, measured serum levels in postmenopausal women with HSDD who were already using testosterone gel alongside estrogen-based HRT as part of their usual care. They found that applying a 5mg daily dose of 1% testosterone gel produced stable serum concentrations within the recommended therapeutic range for women. This data is vital because it confirms that topical gels, which are widely used off-label, can achieve consistent, physiologic levels when used at appropriate doses. It addresses a common concern about under-dosing or erratic absorption.

Long-Term Safety Profile Appears Favorable

Fear of side effects, particularly regarding breast cancer and cardiovascular health, is a major barrier to testosterone therapy. The Florida review synthesizes decades of clinical data and finds these fears may be overstated. At therapeutic doses designed to restore female physiological levels, adverse effects are typically mild and reversible. Acne and mild hair growth are the most frequent issues. Crucially, the authors note that long-term safety data, including evidence from transgender medicine, have not demonstrated increased risks of breast cancer or cardiovascular disease. They argue that supraphysiologic doses, sometimes needed for full symptom relief, are generally well-tolerated. This safety profile is a consistent theme in global guidance, including a New Latin American Position Statement.

A Regulatory Gap Creates a Care Access Problem

The most striking conclusion from the review is a critique of the regulatory environment. The FDA has not approved any testosterone product specifically for women. This forces clinicians and patients into a gray area, relying on off-label use of male-approved products (which requires careful dose adjustment) or compounded therapies from speciality pharmacies. Compounded products lack standardized manufacturing oversight, leading to potential variability in potency, purity, and consistency. This regulatory gap, the authors state, “limits access to standardized, evidence-based care.” It creates an unjust situation where a treatment with a long history of use remains officially unrecognized, leaving women to navigate a complex and often expensive patchwork of options.

Conclusion

Evidence supports testosterone therapy as an effective and generally safe option for postmenopausal women experiencing HSDD. Successful treatment hinges on symptom assessment, not blood tests, and favors transdermal delivery methods. The primary challenge is no longer a lack of clinical evidence but a lack of regulatory approval, which hinders consistent, high-quality patient access. More long-term randomized trials are needed, but existing data provide a robust foundation for its considered use.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42110023/
https://pubmed.ncbi.nlm.nih.gov/41834026/
https://pubmed.ncbi.nlm.nih.gov/38913119/